Scholar Rock Director Akkaraju Buys $12M of Stock in Open-Market Purchases
SRRK sits 57% above its 52-week low of $27.07.
Summary
Scholar Rock director Srinivas Akkaraju bought 289,470 shares for about $12 million in open-market trades on October 23 and 26, lifting his funds' beneficial ownership to roughly 6.38 million shares.
Key Events · Ownership and Investor Activity · SRRK
-
Director Buys $12M in Open Market
Srinivas Akkaraju purchased 289,470 shares for $11,999,922.30 across six transactions on 2026-10-23 and 2026-10-26.
-
Weighted-Average Prices $41.31-$41.59
Purchases were executed at weighted-average prices of $41.31, $41.82 and $41.59, with individual fills ranging from $40.77 to $41.93.
-
Holdings Rise to 6.38 Million Shares
Post-transaction beneficial ownership is 6,380,517 shares, held indirectly through Samsara BioCapital, L.P. and Samsara Opportunity Fund, L.P.
-
Follows September SMA Approval
The buying comes after the FDA approved Isembyld (apitegromab) for spinal muscular atrophy on 2026-09-11 and the U.S. commercial launch began.
Analysis · SRRK · Life Sciences
A director put roughly $12 million of real money into the open market over two trading days, buying 289,470 shares at weighted-average prices between $41.31 and $41.59. That is a meaningful vote of confidence from the board just weeks after the FDA approved Isembyld (apitegromab) for SMA and the U.S. commercial launch began. The purchase is small relative to the company's size, so it is not a thesis-changer on its own, but it is a genuine open-market buy rather than an option exercise or grant, and it comes from an investor-director whose funds now hold about 6.38 million shares.
How filings like this one have moved
In the 30 days to Oct 27, 2026, 29.9% of the 1374 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.12%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, SRRK was trading at $42.49 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $5.2B. The 52-week trading range was $27.07 to $61.76. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.